Next Article in Journal
Current and Prospective Protein Biomarkers of Lung Cancer
Previous Article in Journal
Role of LFA-1 and ICAM-1 in Cancer
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessReview
Cancers 2017, 9(11), 154; https://doi.org/10.3390/cancers9110154

Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology

1
Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, 30 Avenue de la Voie Romaine, 06001 Nice, CEDEX 01, France
2
Côte d’Azur University, FHU OncoAge, 30 Avenue de la Voie Romaine, 06001 Nice, CEDEX 01, France
3
Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, 30 Avenue de la Voie Romaine, 06001 Nice Cedex 01, France
Academic Editor: David Wong
Received: 12 October 2017 / Revised: 6 November 2017 / Accepted: 8 November 2017 / Published: 10 November 2017
View Full-Text   |   Download PDF [248 KB, uploaded 10 November 2017]

Abstract

The practice of liquid biopsy (LB) has revolutionized the care of patients with metastatic lung cancer. Many oncologists now use this approach in daily practice, applying precise procedures for the detection of activating or resistance mutations in EGFR. These tests are performed with plasma DNA and have been approved as companion diagnostic test for patients treated with tyrosine kinase inhibitors. ALK is another important target in lung cancer since it leads to treatment of patients who are positive for a rearrangement in ALK identified with tumor tissue. By analogy with EGFR, LB for detection of genomic alterations in ALK (rearrangements or mutations) has been rapidly adopted in the clinic. However, this promising approach has some limitations and has not yet been disseminated as much as the blood test targeting EGFR. In addition to these two therapeutic targets LB can be used for evaluation of the genomic status of other genes of interest of patients with lung cancer (ROS1, RET, NTRK MET, BRAF, HER2, etc.). LB can be performed to evaluate a specific target or for a more or less complex panel of genes. Considering the number of potential targets for clinical trials, techniques of next-generation sequencing of circulating DNA are on the rise. This review will provide an update on the contribution of LB to care of patients with metastatic lung cancer, including the present limits of this approach, and will consider certain perspectives. View Full-Text
Keywords: liquid biopsy; lung cancer; EGFR; ALK; stratified medicine liquid biopsy; lung cancer; EGFR; ALK; stratified medicine
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Hofman, P. Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology. Cancers 2017, 9, 154.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top